slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
193,621-193,680 of 319,975
03
The slide uses a clean, minimalist layout with a network-style background graphic.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
04
Includes a molecular visualization of the inhibitor binding to the protein.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
05
The slide uses a matrix-like structure to compare drug capabilities against specific clinical requirements.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
06
The slide uses a human anatomy diagram to map specific TRK receptor inhibition (TRKB, TRKC, TRKA) to associated clinical side effects.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide uses a list of icons to represent key clinical attributes of the drug candidate.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide uses dot plots for IC50 values and a bar chart for tumor regression, highlighting NVL-520's performance.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
The chart on the right uses a logarithmic scale for the Selectivity Index.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
10
Includes list of authors and their institutional affiliations.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
11
The slide outlines the clinical trial structure, including patient eligibility criteria and study objectives for both phases.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The slide uses a process-flow style diagram to show how initial cohorts are expanded via back-filling and then filtered into a response-evaluable population.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The slide presents baseline patient characteristics and prior treatment history for a clinical trial cohort.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
Data presented at ENA 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
15
The chart displays a log-scale y-axis for concentration. The data supports once-daily (QD) dosing based on a 20h half-life.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
16
Clinical trial data presentation for ENA 2022.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
17
The chart is a classic waterfall plot used in oncology clinical trials to demonstrate drug efficacy.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
18
The chart is a swimmer plot (often used in oncology to show duration of response/treatment).Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
19
Includes a spider plot (waterfall-like over time) and a bar chart showing allele clearance.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
20
The slide uses a before-after-during progression (Baseline, 4 weeks, 8 weeks) to visualize drug efficacy.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
21
The slide uses a timeline-style list on the left to describe the patient's treatment history and a before-after image grid on the right to show clinical response.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
22
Slide 22 of a conference presentation.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
23
Nuvalent | Investor Presentation Deck | 31 slidesNuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
24
The slide uses a Gantt-style timeline to represent drug development stages.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Beat · Market Size1 hit
25
Nuvalent | Investor Presentation Deck | 31 slidesNuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
26
The slide uses a combination of scatter plots, bar charts, and a waterfall-style selectivity chart to demonstrate drug efficacy and safety profile.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
27
The slide compares vehicle control vs NVL-655 treatment across multiple cell lines and a patient-derived xenograft (PDX) model.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
28
The slide uses a structured table to define patient eligibility criteria for different cohorts in a clinical trial.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
29
Nuvalent | Investor Presentation Deck | 31 slidesNuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
30
The slide uses three distinct chart types to demonstrate drug efficacy and safety profile.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
31
Slide 31 of a corporate presentation.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
01
Organicell Regenerative Medicine | Investor Presentation Deck | 17 slidesOrganicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
02
Organicell Regenerative Medicine | Investor Presentation Deck | 17 slidesOrganicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
03
Includes both stock market data and business financial summary in a side-by-side table format.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
04
Organicell Regenerative Medicine | Investor Presentation Deck | 17 slidesOrganicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
05
The slide uses a timeline-based strategic roadmap to outline short, mid, and long-term business goals.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
06
Organicell Regenerative Medicine | Investor Presentation Deck | 17 slidesOrganicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
07
The slide uses a four-column layout to describe the biological composition of each product.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Beat · Solution1 hit
08
Organicell Regenerative Medicine | Investor Presentation Deck | 17 slidesOrganicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
09
The slide uses a mix of bullet points and checkmarks to categorize technical achievements and market opportunities.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Loop · Voice Of Customer1 hit
10
Includes a scientific diagram illustrating the biogenesis of EVs (exosomes, microvesicles, apoptotic bodies).Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Loop · Voice Of Customer1 hit
11
The slide uses two scientific diagrams to illustrate the biological mechanism and molecular content of exosomes.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
12
The charts are flow cytometry histograms showing CFSE dilution, a standard assay for cell proliferation.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
13
The slide uses a before-after-bridge structure to demonstrate therapeutic efficacy.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
14
Includes longitudinal patient data and representative imaging.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
15
The slide uses a grid layout to categorize patent statuses (Patent Pending vs Provisional Patent) for four distinct product lines.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
16
Includes logos of partner firms at the bottom.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Beat · Team1 hit
17
The slide presents real-time financial data for two publicly traded competitors in the regenerative medicine space.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Beat · Competition1 hit
01
Overstock | Results Presentation Deck | 34 slidesOverstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Attention1 hit
02
Overstock | Results Presentation Deck | 34 slidesOverstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Attention1 hit
03
Overstock | Results Presentation Deck | 34 slidesOverstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Attention1 hit
04
Overstock | Results Presentation Deck | 34 slidesOverstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Attention1 hit
05
The slide uses a combination of absolute revenue growth and YoY percentage trends to demonstrate business stabilization.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Need1 hit
06
Overstock | Results Presentation Deck | 34 slidesOverstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Need1 hit
07
Includes a list of brand ambassadors and a metric regarding their aggregate social media following.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Need1 hit
08
Overstock | Results Presentation Deck | 34 slidesOverstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Need1 hit
09
Includes footnotes regarding non-GAAP measures and continuing operations.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Need1 hit
10
The chart includes a trend line annotation showing a 33% decline from Q3 '21 to Q3 '22.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
11
The chart displays a dual-axis view of gross margin performance over time.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
12
The chart uses a combination of bar (absolute $) and line (percentage) to show trends.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
13
The chart highlights a decline in both absolute EBITDA and margin percentage over the two-year period.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
14
The chart combines a bar chart for active customers and a line chart for order frequency.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit